Marizomib is a novel, brain-penetrant proteasome inhibitor, which inhibits all three proteasome subunits.

Celgene (now part of Bristol-Myers Squibb) acquired the assets related to marizomib from Triphase in November 2016 and Triphase continues to support Bristol-Myers Squibb with development – including completing a Phase 2 study in recurrent glioma and a Phase 1 study in newly diagnosed glioma. Marizomib is currently being evaluated in a global, Phase 3 clinical study (NCT03345095) in combination with Temozolomide (Temodar®) and radiotherapy in patients with newly diagnosed Grade IV malignant glioma (glioblastoma).

Marizomib has received Orphan Drug designation in glioblastoma in the United States from the FDA and has received Orphan Drug designation in multiple myeloma in the United States and the European Union.